The glipizide controlled release tablet is a drug suitable for patients with mild and moderate type 2 diabetes who cannot be satisfactorily controlled by diet therapy alone.
The global Glipizide Controlled Release Tablet market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Glipizide Controlled Release Tablet is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Glipizide Controlled Release Tablet is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Glipizide Controlled Release Tablet include Pfizer, Teva, NOVARTIS, Beijing Tianan, Hainan Jinxiao, Shanghai Xinyi, Zhuhai Federation, Changzhou Siyao Pharmaceutical and Disa Pharmaceutical, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glipizide Controlled Release Tablet, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glipizide Controlled Release Tablet.
The Glipizide Controlled Release Tablet market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Glipizide Controlled Release Tablet market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glipizide Controlled Release Tablet manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Pfizer
Teva
NOVARTIS
Beijing Tianan
Hainan Jinxiao
Shanghai Xinyi
Zhuhai Federation
Changzhou Siyao Pharmaceutical
Disa Pharmaceutical
Walvax
Segment by Type
2.5mg
5mg
10mg
Segment by Application
Medical
Research Laboratories
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Glipizide Controlled Release Tablet manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Glipizide Controlled Release Tablet in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Glipizide Controlled Release Tablet Market Overview
1.1 Product Overview and Scope of Glipizide Controlled Release Tablet
1.2 Glipizide Controlled Release Tablet Segment by Type
1.2.1 Global Glipizide Controlled Release Tablet Market Value Comparison by Type (2023-2029)
1.2.2 2.5mg
1.2.3 5mg
1.2.4 10mg
1.3 Glipizide Controlled Release Tablet Segment by Application
1.3.1 Global Glipizide Controlled Release Tablet Market Value by Application: (2023-2029)
1.3.2 Medical
1.3.3 Research Laboratories
1.3.4 Others
1.4 Global Glipizide Controlled Release Tablet Market Size Estimates and Forecasts
1.4.1 Global Glipizide Controlled Release Tablet Revenue 2018-2029
1.4.2 Global Glipizide Controlled Release Tablet Sales 2018-2029
1.4.3 Global Glipizide Controlled Release Tablet Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Glipizide Controlled Release Tablet Market Competition by Manufacturers
2.1 Global Glipizide Controlled Release Tablet Sales Market Share by Manufacturers (2018-2023)
2.2 Global Glipizide Controlled Release Tablet Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Glipizide Controlled Release Tablet Average Price by Manufacturers (2018-2023)
2.4 Global Glipizide Controlled Release Tablet Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Glipizide Controlled Release Tablet, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glipizide Controlled Release Tablet, Product Type & Application
2.7 Glipizide Controlled Release Tablet Market Competitive Situation and Trends
2.7.1 Glipizide Controlled Release Tablet Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Glipizide Controlled Release Tablet Players Market Share by Revenue
2.7.3 Global Glipizide Controlled Release Tablet Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Glipizide Controlled Release Tablet Retrospective Market Scenario by Region
3.1 Global Glipizide Controlled Release Tablet Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Glipizide Controlled Release Tablet Global Glipizide Controlled Release Tablet Sales by Region: 2018-2029
3.2.1 Global Glipizide Controlled Release Tablet Sales by Region: 2018-2023
3.2.2 Global Glipizide Controlled Release Tablet Sales by Region: 2024-2029
3.3 Global Glipizide Controlled Release Tablet Global Glipizide Controlled Release Tablet Revenue by Region: 2018-2029
3.3.1 Global Glipizide Controlled Release Tablet Revenue by Region: 2018-2023
3.3.2 Global Glipizide Controlled Release Tablet Revenue by Region: 2024-2029
3.4 North America Glipizide Controlled Release Tablet Market Facts & Figures by Country
3.4.1 North America Glipizide Controlled Release Tablet Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Glipizide Controlled Release Tablet Sales by Country (2018-2029)
3.4.3 North America Glipizide Controlled Release Tablet Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Glipizide Controlled Release Tablet Market Facts & Figures by Country
3.5.1 Europe Glipizide Controlled Release Tablet Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Glipizide Controlled Release Tablet Sales by Country (2018-2029)
3.5.3 Europe Glipizide Controlled Release Tablet Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glipizide Controlled Release Tablet Market Facts & Figures by Country
3.6.1 Asia Pacific Glipizide Controlled Release Tablet Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Glipizide Controlled Release Tablet Sales by Country (2018-2029)
3.6.3 Asia Pacific Glipizide Controlled Release Tablet Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Glipizide Controlled Release Tablet Market Facts & Figures by Country
3.7.1 Latin America Glipizide Controlled Release Tablet Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Glipizide Controlled Release Tablet Sales by Country (2018-2029)
3.7.3 Latin America Glipizide Controlled Release Tablet Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Glipizide Controlled Release Tablet Market Facts & Figures by Country
3.8.1 Middle East and Africa Glipizide Controlled Release Tablet Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Glipizide Controlled Release Tablet Sales by Country (2018-2029)
3.8.3 Middle East and Africa Glipizide Controlled Release Tablet Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Glipizide Controlled Release Tablet Sales by Type (2018-2029)
4.1.1 Global Glipizide Controlled Release Tablet Sales by Type (2018-2023)
4.1.2 Global Glipizide Controlled Release Tablet Sales by Type (2024-2029)
4.1.3 Global Glipizide Controlled Release Tablet Sales Market Share by Type (2018-2029)
4.2 Global Glipizide Controlled Release Tablet Revenue by Type (2018-2029)
4.2.1 Global Glipizide Controlled Release Tablet Revenue by Type (2018-2023)
4.2.2 Global Glipizide Controlled Release Tablet Revenue by Type (2024-2029)
4.2.3 Global Glipizide Controlled Release Tablet Revenue Market Share by Type (2018-2029)
4.3 Global Glipizide Controlled Release Tablet Price by Type (2018-2029)
5 Segment by Application
5.1 Global Glipizide Controlled Release Tablet Sales by Application (2018-2029)
5.1.1 Global Glipizide Controlled Release Tablet Sales by Application (2018-2023)
5.1.2 Global Glipizide Controlled Release Tablet Sales by Application (2024-2029)
5.1.3 Global Glipizide Controlled Release Tablet Sales Market Share by Application (2018-2029)
5.2 Global Glipizide Controlled Release Tablet Revenue by Application (2018-2029)
5.2.1 Global Glipizide Controlled Release Tablet Revenue by Application (2018-2023)
5.2.2 Global Glipizide Controlled Release Tablet Revenue by Application (2024-2029)
5.2.3 Global Glipizide Controlled Release Tablet Revenue Market Share by Application (2018-2029)
5.3 Global Glipizide Controlled Release Tablet Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Glipizide Controlled Release Tablet Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Teva Glipizide Controlled Release Tablet Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 NOVARTIS
6.3.1 NOVARTIS Corporation Information
6.3.2 NOVARTIS Description and Business Overview
6.3.3 NOVARTIS Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.3.4 NOVARTIS Glipizide Controlled Release Tablet Product Portfolio
6.3.5 NOVARTIS Recent Developments/Updates
6.4 Beijing Tianan
6.4.1 Beijing Tianan Corporation Information
6.4.2 Beijing Tianan Description and Business Overview
6.4.3 Beijing Tianan Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Beijing Tianan Glipizide Controlled Release Tablet Product Portfolio
6.4.5 Beijing Tianan Recent Developments/Updates
6.5 Hainan Jinxiao
6.5.1 Hainan Jinxiao Corporation Information
6.5.2 Hainan Jinxiao Description and Business Overview
6.5.3 Hainan Jinxiao Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Hainan Jinxiao Glipizide Controlled Release Tablet Product Portfolio
6.5.5 Hainan Jinxiao Recent Developments/Updates
6.6 Shanghai Xinyi
6.6.1 Shanghai Xinyi Corporation Information
6.6.2 Shanghai Xinyi Description and Business Overview
6.6.3 Shanghai Xinyi Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Shanghai Xinyi Glipizide Controlled Release Tablet Product Portfolio
6.6.5 Shanghai Xinyi Recent Developments/Updates
6.7 Zhuhai Federation
6.6.1 Zhuhai Federation Corporation Information
6.6.2 Zhuhai Federation Description and Business Overview
6.6.3 Zhuhai Federation Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Zhuhai Federation Glipizide Controlled Release Tablet Product Portfolio
6.7.5 Zhuhai Federation Recent Developments/Updates
6.8 Changzhou Siyao Pharmaceutical
6.8.1 Changzhou Siyao Pharmaceutical Corporation Information
6.8.2 Changzhou Siyao Pharmaceutical Description and Business Overview
6.8.3 Changzhou Siyao Pharmaceutical Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Changzhou Siyao Pharmaceutical Glipizide Controlled Release Tablet Product Portfolio
6.8.5 Changzhou Siyao Pharmaceutical Recent Developments/Updates
6.9 Disa Pharmaceutical
6.9.1 Disa Pharmaceutical Corporation Information
6.9.2 Disa Pharmaceutical Description and Business Overview
6.9.3 Disa Pharmaceutical Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Disa Pharmaceutical Glipizide Controlled Release Tablet Product Portfolio
6.9.5 Disa Pharmaceutical Recent Developments/Updates
6.10 Walvax
6.10.1 Walvax Corporation Information
6.10.2 Walvax Description and Business Overview
6.10.3 Walvax Glipizide Controlled Release Tablet Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Walvax Glipizide Controlled Release Tablet Product Portfolio
6.10.5 Walvax Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Glipizide Controlled Release Tablet Industry Chain Analysis
7.2 Glipizide Controlled Release Tablet Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glipizide Controlled Release Tablet Production Mode & Process
7.4 Glipizide Controlled Release Tablet Sales and Marketing
7.4.1 Glipizide Controlled Release Tablet Sales Channels
7.4.2 Glipizide Controlled Release Tablet Distributors
7.5 Glipizide Controlled Release Tablet Customers
8 Glipizide Controlled Release Tablet Market Dynamics
8.1 Glipizide Controlled Release Tablet Industry Trends
8.2 Glipizide Controlled Release Tablet Market Drivers
8.3 Glipizide Controlled Release Tablet Market Challenges
8.4 Glipizide Controlled Release Tablet Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Pfizer
Teva
NOVARTIS
Beijing Tianan
Hainan Jinxiao
Shanghai Xinyi
Zhuhai Federation
Changzhou Siyao Pharmaceutical
Disa Pharmaceutical
Walvax
*If Applicable.